Download PDF

Mitochondrial DNA and HeritableTraits and Diseases¶

Chapter 481 | Part 16: Genes, the Environment, and Disease · Parts 15-16 – Genetics, Genomics & Precision Medicine · Chapter 481

Key Clinical Points¶

Mitochondria are essential for ATP production via oxidative phosphorylation (OXPHOS) and manage critical processes like apoptosis and calcium homeostasis.
Dual genetic control: ~1400 genes from nuclear DNA (nDNA) and 37 genes from mitochondrial DNA (mtDNA).
mtDNA is inherited exclusively through the maternal line; paternal mtDNA is degraded after fertilization.
Heteroplasmy: The coexistence of wild-type and mutant mtDNA within a cell. Disease expression depends on the threshold of mutant load.
The 'mitochondrial bottleneck' during oogenesis leads to varying levels of heteroplasmy in offspring, causing significant phenotypic variability.
LHON (Leber's Hereditary Optic Neuropathy) is a notable example where mutations are often homoplasmic.
Clinical clues for mtDNA disease include: maternal inheritance without paternal transmission, multi-system involvement, and evidence of impaired cellular energetics (e.g., lactic acidosis, 'ragged red fibers').
Diagnostic investigation follows a structured progression: Initial Screening → Genetic Selection → Tissue-specific analysis.
Mitochondrial Replacement Techniques (MRT), including Maternal Spindle Transfer and Pronuclear Transfer, can prevent the transmission of mtDNA mutations.
Pharmacogenetics identifies genes like TPMT, dihydropyrimidine dehydrogenase, malignant hyperthermia, and G6PD that influence drug metabolism and safety.

DEFINITION & OVERVIEW¶

• Mitochondria: Cytoplasmic organelles primarily responsible for generating ATP via oxidative phosphorylation (OXPHOS) under aerobic conditions. • Oxidative Phosphorylation: Mediated by respiratory electron transport chain (ETC) multiprotein enzyme complexes I–V and the two electron carriers, coenzyme Q (CoQ) and cytochrome c, located in the inner mitochondrial membrane. • Additional Functions: Calcium homeostasis, apoptosis (programmed cell death), and free radical production. • Clinical Significance: Because OXPHOS is essential for almost all cells, mitochondrial dysfunction can affect nearly any organ system. • Pathophysiology: Driven by both mtDNA mutations and potentially by free radical production and the redox state of the mitochondria.

Definition (Harrison's 22e): Mitochondrial DNA (mtDNA) and Heritable Traits and Diseases encompass disorders related to the mtDNA component of the dual genetic control of mitochondrial function.

Mitochondrial Structure and Function¶

• Dual Genetic Control: ◦ Nuclear DNA (nDNA): ≈1400 gene products; follow nuclear genomic inheritance. ◦ Mitochondrial DNA (mtDNA): 37 genes; includes 13 for ETC components and 24 for tRNA/rRNA translation. • mtDNA Characteristics: ◦ Circular, double-strand molecule of 16,569 nucleotides. ◦ Replicates independently of cell division using polymerase gamma (polγ, encoded by the nuclear gene POLG). • Polgallon Mutations: Can lead to somatic mutations in mtDNA or mtDNA depletion; not heritable unless mutation occurs and is propagated in the oocyte.

Table 481-1: Functions of Mitochondria - All Cells/Tissues: Oxidative phosphorylation, Free radical production, Calcium homeostasis, Apoptosis. - Tissue-Specific: Cholesterol metabolism, Amino and organic acid metabolism, Fatty acid β-oxidation, Sex steroid synthesis, Heme synthesis, Hepric ammonia detoxification, Neurotransmitter metabolism.

EPIDEMIOLOGY¶

• Prevalence: Difficult to estimate due to phenotypic heterogeneity caused by varying levels of heteroplasmy. • Pharmacogenetics: Identifies genes that alter drug metabolism or confer susceptibility to toxic drug reactions. ◦ Examples: TPMT deficiency, dihydropyrimidine dehydrogenase deficiency, malignant hyperthermia, and G6PD deficiency. ◦ Note: While linked to CYP2C6 and VKORC1 for warfarin, there is no evidence that incorporating genotyping into clinical practice improves patient outcomes compared with clinical algorithms.

• Maternal Inheritance: ◦ Only maternal DNA is transmitted to offspring. ◦ Paternal mitochondria are degraded via the ubiquitin proteasome system and autophagy on the inner membrane of the oocyte. ◦ Sperm lack intact mtDNA and are missing TFAM (mitochondrial transcription factor). • Clinical Implications: ◦ Both sons and daughters have equal chances of disease. ◦ Exception: LHON (where mutations are often homoplasmic). • Evidence of Origin: ◦ Paternal transmission → excludes mitochondrial origin. ◦ Maternal inheritance without paternal transmission → strongly suggests a heritable mtDNA disorder.

ETIOLOGY & PATHOPHYSIOLOGY¶

• Somatic Mutations: ◦ High mutation rate in mtDNA leads to accumulation of mutations with age. ◦ Potential contribution to age-related diseases (metabolic syndrome, cancer, neurodegeneration). • Heteroplasmy: Coexistence of wild-type and mutant mtDNA molecules within a cell, tissue, or individual. • Mitotic Segregation: Unequal distribution of mtDNA molecules during cell division; leads to 'mitochondrial bottleneck' effects. • Threshold Effect: ◦ Phenotypic expression is a function of the inherent pathogenicity and the distribution among multiple copies of mtDNA. • Homoplasmy: All mtDNA molecules share the same sequence; often results from 'bottleneck' and genetic drift during oogenesis. ◦ Homoplasmic mutations are typically not heritable unless they occur in the germline.

mtDNA Structure and Replication¶

• Replication: Independent of cell cycle; results in varying copy numbers across tissues. ◦ Reduced proofreading/correction leads to high mutation rates compared to nuclear DNA. • Transcription: Initiates on both strands; produces polycistronic precursor RNA processed into 13 mRNA and 24 tRNA/rRNA. • Genome Organization: ◦ Coding region: 93% of the 16,569 nucleotides. ◦ Control region (D-loop): Essential for replication/transcription initiation. • Ecogenetic Mutations: Remain silent until an external event occurs (e.g., m.1555A>G in 12S rRNA causing hearing loss only after aminoglycoside exposure)."

Pathogenicity and Thresholds¶

• Mechanism of Disease: ◦ Defective ATP production (ETC disruption) OR increased ROS generation. • Phenotypic Heterogeneity: ◦ Same mutation → different phenotypes in different patients. ◦ Different mutations → overlapping clinical features. ◦ This makes genotype-phenotype correlation challenging.

CLINICAL FEATURES¶

• Clinical Clues for Mitochondrial Disease: 1. Familial clustering with absence of paternal transmission. 2. Multi-system involvement (e.g., myopathy + neurodegeneration) that do not fit into a single nuclear genomic mutation category. 3. Laboratory/Pathologic markers: Lactic acidosis, "Ragged Red Fibers" (accumulation of abnormal mitochondria under the muscle sarcolemmal membrane). 4. Mosaic pattern reflecting a heteroplasmic state.

Common Features by System¶

Table 481-2: Common Features of Mitochondrial DNA–Associated Diseases in Adults - Neurologic: stroke, epilepsy, migraine headache, peripheral neuropathy, ataxia, dystonia, myoclonus, cranial neuropathy (optic atrophy, sensorineural deafness, dysphagia, dysphasia). - Skeletal myopathy: ophthalmoplegia, exercise intolerance, myalgia, weakness. - Cardiac: conduction block, cardiomyopathy. - Respiratory: hypoventilation, aspiration pneumonitis. - Endocrine: diabetes mellitus, premature ovarian failure, hypothyroidism, hypoparathyroidism. - Ophthalmologic: cataracts, pigment retinopathy, optic atrophy, ophthalmoplegia.

DIFFERENTIAL DIAGNOSIS¶

• Distinguishing Features: ◦ Mitochondrial disorders often present as a combination of symptoms that do not fit into a single nuclear mutation category. ◦ Differentiation from other myopathies: Presence of "Ragged Red Fibers" and lactic acidosis.

DIAGNOSTIC APPROACH¶

Initial Screening:
Clinical history (family pedigree) → Physical exam.
Biochemical evaluation (e.g., lactate levels).
Genetic Selection (based on technology/cost):
Option A: Specific mtDNA point mutations with LR-PCR.
Option B: Whole mtDNA genome (NextGen) with LR-PCR.
Option C: WES or WGS (including mtDNA genome) with LR-PCR.
Tissue-specific analysis:
Immunohistochemistry.
Muscle Biopsy.
Respiratory Chain Enzymology.
Specialized Muscle Analysis (if biopsy performed):
LR-PCR (mtDNA).
Whole genome sequencing.
mtDNA copy number quantification.

Flowchart 1: Clinical and Laboratory Investigation¶

Step 1: Patient presents with suspected symptoms → Initial Biochemical Screening (Clinical history, exam, and biochemical evaluation). Step 2: Genetic Selection based on availability → Select one of three modalities: Specific mtDNA point mutations (LR-PCR), Whole mtDNA genome (NextGen/LR-PCR), or WES/WGS (including mtDNA genome/LR-PCR). Step 3: Tissue-specific analysis → Perform Immunohistochemistry, Muscle Biopsy, and Respiratory Chain Enzymology. Step 4: If muscle biopsy is performed → Proceed to specialized analysis: LR-PCR (mtDNA), whole genome sequencing, or copy number quantification.

MANAGEMENT & TREATMENT¶

Symptom Management: Targeted treatment of specific organ involvement (e.g., seizures, cardiomyopathy).
Environmental Modification:
Identify and remove triggers (e.g., avoid tobacco in patients with LHON).
Mitochondrial Replacement Techniques (MRT):
Maternal Spindle Transfer: Replace mutant mitochondria from mother with donor mitochondria before fertilization.
Pronuclear Transfer: Replace pronucleus of a fertilized egg containing mutant mtDNA with one from a donor's egg.

Flowchart 2: Pathways of mtDNA Damage and Aging¶

Mitochondrial Oxidative Phosphorylation → Production of Reactive Oxygen Species (ROS).
ROS → Nuclear DNA damage → Apoptosis → Aging.
ROS → Apoptosis → Aging.
Critical Threshold:
Damage to mitochondrial energy-generating apparatus exceeds "function threshold" → Release of proteins → Activate caspase pathway → Apoptosis → Aging.

COMPLICATIONS & PROGNOSIS¶

• Prognostic Factors: - Degree of heteroplasmy. - Specific mutation location (e.g., tRNA mutations vs. protein-coding). - Age at onset and rate of progression.

Specific Syndromes¶

Table 481-3: Mitochondrial Diseases Due to mtDNA Point Mutations and Large-Scale Rearrangements - NARP, Leigh’s syndrome: m.1778G>A, m.14484T>C, m.3460G>A (Heteroplasmic; Maternal). - MELAS: Point mutation in tRNAleu (m.A3243G) (Heteroplasmic). - MERRF: Point mutation in tRNAlys (Heteroplasmic; Maternal). - Deafness: m.1555A>G or m.7445A>G in 12S rRNA (Homoplasmic). - PEO: Single deletions/duplications (Heteroplasmic; mostly somatic). - KSS: 5-kb "common deletion" (Heteroplasmic; somatic).

SPECIAL CONSIDERATIONS¶

• Pediatric Patients: - Often present with early-onset symptoms (e.g., Leigh syndrome, MELAS). - Require specialized imaging to identify basal ganglia/brainstem involvement. • Reproductive Medicine: - Use of MRT for women with known pathogenic mtDNA mutations to ensure offspring have healthy mitochondria.

Genomic Landscape¶

• Mitochondrial Genome Map (Figure 6/7): - Protein-coding genes: ND1, ND2, ND3, ND4, ND4L, ND5, ND6, COX I, COXII, COXIII. - tRNA/rRNA genes: F, G, H, K, L, M, N, P, Q, R, S, T. - Associated conditions include cardiomyopathy, myopathy, and various neurological deficits.

KEY PEARLS & CLINICAL TRAPS¶

• Heteroplasmy Rule: eq 100% mutation required for disease; threshold of mutant load determines clinical expression. • Maternal Line Only: If a condition shows paternal transmission, it is likely not an mtDNA disorder. • LHON Exception: A case where mutations are often homoplasmic (100%). • Ragged Red Fibers: Not specific to mtDNA disease but highly suggestive of mitochondrial dysfunction in muscle. • Mitochondrial Replacement: Spindle and Pronuclear transfer allow for "three-parent" babies to bypass maternal mtDNA defects.

Reference Tables¶

TABLE 481-1 Functions of Mitochondria All Cells and Tissues Oxidative phosphorylation Free radical production Calcium…¶

Harrison's 22e, p.3806

All Cells and Tissues
Oxidative phosphorylation
Free radical production
Calcium homeostasis
Apoptosis (programmed cell death)
Tissue- or Cell-Specific
Cholesterol metabolism
Amino and organic acid metabolism
Fatty acid beta oxidation
Sex steroid synthesis
Heme synthesis
Hepatic ammonia detoxification
Neurotransmitter metabolism

TABLE 481-2 Common Features of Mitochondrial DNA–Associated Diseases in Adults Neurologic: stroke, epilepsy, migraine…¶

Harrison's 22e, p.3811

Neurologic: stroke, epilepsy, migraine headache, peripheral neuropathy, ataxia,
dystonia, myoclonus, cranial neuropathy (optic atrophy, sensorineural deafness,
dysphagia, dysphasia)
Skeletal myopathy: ophthalmoplegia, exercise intolerance, myalgia, weakness
Cardiac: conduction block, cardiomyopathy
Respiratory: hypoventilation, aspiration pneumonitis
Endocrine: diabetes mellitus, premature ovarian failure, hypothyroidism,
hypoparathyroidism
Ophthalmologic: cataracts, pigment retinopathy, neurologic and myopathic (optic
atrophy, ophthalmoplegia)

TABLE 481-3 Mitochondrial Diseases Due to Mitochondrial DNA (mtDNA) Point Mutations and Large-Scale Rearrangements¶

Harrison's 22e, p.3811

DISEASE	PHENOTYPE	MOST FREQUENT mtDNA MUTATIONS	HETEROPLASMIC/ HOMOPLASMIC	MATERNAL
NARP, Leigh’s syndrome	Loss of central vision leading to blindness in young adult life	m.1778G>A, m.14484T>C, m.3460G>A	Heteroplasmic	Maternal
	Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes; may manifest only as diabetes mellitus	Point mutation in tRNAleu	Heteroplasmic
MERRF	Myoclonic epilepsy, ragged red fibers in muscle, ataxia, increased CSF protein, sensorineural deafness, dementia	Point mutation in tRNAlys	Heteroplasmic	Maternal
	Progressive sensorineural deafness, often induced by aminoglycoside antibiotics	m.1555A>G mutation in 12S rRNA	Homoplasmic
	Nonsyndromic sensorineural deafness	m.7445A>G mutation in 12S rRNA	Homoplasmic
Chronic progressive external ophthalmoplegia (PEO)	Late-onset bilateral ptosis and ophthalmoplegia, proximal muscle weakness, and exercise intolerance	Single deletions or duplications	Heteroplasmic	Mostly sporadic, somatic mutations
	Pancreatic insufficiency, pancytopenia, lactic acidosis	Large deletion	Heteroplasmic
Kearns-Sayre syndrome (KSS)	External ophthalmoplegia, heart block, retinal pigmentation, ataxia	The 5-kb “common deletion”	Heteroplasmic	Sporadic, somatic mutations